ZCCHC2 and acute promyelocytic leukemia: Previous studies have linked ZCCHC2 to immunity and resistance in lymphoma, acute lymphoblastic leukemia, AML, acute promyelocytic leukemia (APL), and chronic lymphocytic leukemia (CLL)19,20.